# Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients

> **NCT01010880** · PHASE1,PHASE2 · COMPLETED · sponsor: **Biokine Therapeutics Ltd** · enrollment: 16 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** BKT140

## Key facts

- **NCT ID:** NCT01010880
- **Lead sponsor:** Biokine Therapeutics Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2011-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01010880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01010880, "Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01010880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*